GlassScriptPhysician profile
Marilyn Huang
NPI 1982856175
$39,194.51
in general payments reported to CMS, 2019-2025
16 companies · $4,668 in 2025
The $4,668 reported for 2025 was more than what 86% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,814 · 2020: $1,718 · 2021: $5,286 · 2022: $7,332 · 2023: $5,803 · 2024: $8,574 · 2025: $4,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,575 · Food and Beverage: $1,274 · Travel and Lodging: $1,208 · Education: $2.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,985.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,575.00 |
| Food and Beverage | $1,274.33 |
| Travel and Lodging | $1,208.45 |
| Education | $2.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $8,161.72 | 2021-2025 | |
| Seagen INC. | $8,119.66 | 2020-2023 | Tivdak |
| Coopersurgical, INC. | $4,275.00 | 2021-2022 | |
| Tesaro, INC. | $4,228.98 | 2019 | |
| Eisai INC. | $3,268.79 | 2022 | |
| Glaxosmithkline, LLC. | $2,523.34 | 2020-2024 | Jemperli, Zejula |
| Astrazeneca Pharmaceuticals LP | $1,851.35 | 2022-2024 | Lynparza |
| Pfizer INC. | $1,770.99 | 2024 | |
| Immunogen, INC. | $1,593.69 | 2023-2024 | Elahere, Elahere |
| Clovis Oncology, INC. | $1,585.00 | 2019 | |
| Karyopharm Therapeutics INC. | $1,430.94 | 2023 | Xpovio |
| Abbvie INC. | $188.13 | 2025 | |
| Myriad Genetic Laboratories, INC. | $118.80 | 2022-2023 | Mychoice Cdx |
| Puma Biotechnology, INC. | $75.72 | 2020 | |
| Intuitive Surgical, INC. | $2.40 | 2023 | Da Vinci Surgical System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marilyn Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.